The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Liquid biopsy cancer screening: We’ll need more than one size to fit all

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Liquid biopsy tests may someday upend screening as we know it. The promise of broad screening employing “multi-cancer detection” has spawned consortia and inspired enthusiastic opinion articles. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Peter B. Bach, MD
Chief medical officer, Delfi Diagnostics
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves first companion diagnostic for lung cancer drug

FDA has approved FoundationOne Liquid CDx to be used as a companion diagnostic for Tepmetko (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. Tepmetko received accelerated approval from FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer harboring mesenchymal-epithelial transition exon 14 skipping alterations. FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for Tepmetko.
Drugs & Targets

CHMP issues positive opinion of Sarclisa for transplant-ineligible newly diagnosed MM

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. A final decision is expected in the coming months.
In Brief

UCLA researchers awarded $2.5M grant from BMS Foundation to increase lung cancer screening in underserved communities

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County. 
Byline
Peter B. Bach, MD
Chief medical officer, Delfi Diagnostics
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account